Detailed Narrative
USFDA Gagillapur Facility OAI & Remediation Efforts
The USFDA classified the inspection of Granules' Gagillapur finished dosage facility (August 26 - September 6) as 'Official Action Indicated' (OAI), following six Form 483 observations. The company has undertaken a proactive and comprehensive remediation plan, with 90% of Corrective and Preventive Actions (CAPAs) completed and the remainder on track for closure by March '25. Operations and dispatches resumed in October after a voluntary pause in September for risk assessment, and Granules is maintaining continuous communication with the FDA, including monthly progress updates.
Q3 FY25 Financial Performance Overview
Granules India reported Q3 FY25 revenue of INR 11,377 million, a 2% decline year-on-year but an 18% improvement quarter-on-quarter. Gross margins expanded significantly to 61.7% in Q3 FY25, up 474 basis points year-on-year, driven by profitable sales growth of finished dosages. However, EBITDA for the quarter was INR 2,303 million (20.2% of sales), decreasing by 144 basis points year-on-year and 80 basis points quarter-on-quarter, primarily due to one-off📎 costs.
Impact of One-off Costs on Margins
EBITDA margins in Q3 FY25 were impacted by approximately $3 million in one-off📎 expenses, including consultancy fees for remediation, failure-to-supply costs, and increased air freight charges. Management indicated that about 50% of these costs might recur in Q4 FY25, albeit at a reduced level. This explains the sequential decline in EBITDA margin despite strong gross margin performance.
Growth Strategy and Product Pipeline
The company's growth trajectory remains robust and diversified, with a focus on new product launches from its GPI site for the US market, particularly in the CNS ADHD segment. Granules has 83 ANDAs in the US (15 awaiting approval), 12 applications in Europe (4 awaiting approval), and 15 applications in the rest of the world (8 awaiting approval). R&D spend for Q3 FY25 was INR 568 million, up from INR 468 million in Q3 FY24, reflecting continued investment in its pipeline, including oncology and antidiabetic segments.
Capacity Expansion at Genome Valley (GLS)
Granules' new formulation facility at Genome Valley under Granules Life Sciences is progressing well. Phase I, with a capacity of 2.5 billion doses, has been commissioned, and commercial dispatches of monograph products have commenced. Phase II, adding an additional 7.5 billion dose capacity, is expected to be commissioned by Q4 FY25, with validation activities slated for Q1 FY26, bringing the total planned capacity to 10 billion doses. The company expects a European inspection for this facility in late March or early April.
Capex and Debt Management
Capex spend during Q3 FY25 was INR 1,335 million, primarily invested in Granules Life Sciences (INR 940 million). Year-to-date capex stands at INR 4,102 million, with INR 2,425 million for GLS. For FY26, the company estimates capex to be 'anywhere between INR500-odd crores.' Net debt increased slightly to INR 8,289 million in Q3 FY25 from INR 7,973 million in Q2 FY25, but management emphasized that they are not taking additional borrowings and cash flow from operations is managed well.